Fibrosis Hepática
Pirfenidone effectively reverses experimental liver fibrosis
Fibrogenic Polymorphisms (TGF-β, PAI-1, AT) in Mexican Patients With Established Liver Fibrosis. Potential Correlation With Pirfenidone Treatment
Therapeutic targets in liver fibrosis
Inflammatory status in human hepatic cirrhosis
Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases
Hepatología clínica y trasplante hepático. Fascículo 8
Now There Are Many (Stages) Where Before There Was One: In Search of a Pathophysiological Classification of Cirrhosis
Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes
Reversal of liver cirrhosis: current evidence and expectations
Potent antioxidant role of Pirfenidone in experimental cirrhosis
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Hepatología clínica y trasplante hepático. Fascículo 7
Hepatología clínica y trasplante hepático. Fascículo 6
Hepatología clínica y trasplante hepático. Fascículo 5
Hepatología clínica y trasplante hepático. Fascículo 4
